TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34923679

Group type: EXPERIMENTAL
Intervention: Workshop with the PE teachers
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Workshop with the PE teachers + Doubling PE classes
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Doubling physical education (PE) classes
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Control group (1:40 h of PE/week)
Number of subjects: 1279
Study: 32236346

Group type: EXPERIMENTAL
Intervention: Educational plan for self-management
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional educational plan
Number of subjects: 20
Study: 33164945

Group type: EXPERIMENTAL
Intervention: 24-hour infusion of levodopa/carbidopa (720/90 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 14-hour 'waking-day' infusion of levodopa/carbidopa (538/68 mg plus a morning oral dose of 150/15 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (24-hour and 14-hour)
Number of subjects: 38
Study: 32451212

Group type: EXPERIMENTAL
Intervention: Trivalent live human-lamb reassortant rotavirus vaccine (LLR3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36424552

Group type: EXPERIMENTAL
Intervention: Transtheoretical model group
Number of subjects: 194

Group type: COMPARATOR
Intervention: Non-transtheoretical model group
Number of subjects: 194
Study: 33355838

Group type: EXPERIMENTAL
Intervention: Routine PICC access
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual IV access
Number of subjects: 66
Study: 35151280

Group type: EXPERIMENTAL
Intervention: Mictalase® suppositories (Phenolmicin P3 and Bosexil) administered twice a day for 5 days, then once a day for 10 days
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no Mictalase®)
Number of subjects: 111
Study: 33606302

Group type: EXPERIMENTAL
Intervention: Balance Training followed by Explosive Strength Training (BT-ET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explosive Strength Training followed by Balance Training (ET-BT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (BT-ET and ET-BT)
Number of subjects: 0
Study: 32257441

Group type: EXPERIMENTAL
Intervention: Unintended pregnancy prevalence
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Family size ≥ 6
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: No communication about family planning with husbands
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Parity ≥ 5
Number of subjects: 612
Study: 34267167

Group type: COMPARATOR
Intervention: Auto-pulse mode (group A)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Single-pulse mode (group B)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 33075644

Group type: EXPERIMENTAL
Intervention: iAx (instant assessment and feedback system)
Number of subjects: 87

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both iAx and TAU
Number of subjects: 87
Study: 32709656

Group type: EXPERIMENTAL
Intervention: TAU+ACT
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: TAU+BATD
Number of subjects: 225

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Physiological variables
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Polymorphisms in FKBP5 gene
Number of subjects: 225
Study: 35507481

Group type: EXPERIMENTAL
Intervention: ZF2001 vaccine (25-μg doses, 3 doses, 30 days apart)
Number of subjects: 25873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25873
Study: 35604960

Group type: EXPERIMENTAL
Intervention: Topical 10 mg Z-endoxifen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Topical 20 mg Z-endoxifen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 33993571

Group type: EXPERIMENTAL
Intervention: alfentanil 14 mcg kg−1
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: rocuronium 0.3 mg kg−1
Number of subjects: 114

Group type: COMPARATOR
Intervention: propofol 2 mg kg−1
Number of subjects: 114
Study: 35404157

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cycle ergometer training
Number of subjects: 102
Study: 34655071

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection of autologous mesenchymal stem cells (50-60 ×106 cells)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection of autologous mesenchymal stem cells
Number of subjects: 20
Study: 32773165

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins, hydroxychloroquine, and ritonavir/lopinavir
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Corticoids
Number of subjects: 238
Study: 35491578

Group type: EXPERIMENTAL
Intervention: Collum Femoris Preserving stem (CFP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Corail stem
Number of subjects: 71
Study: 33544521

Group type: EXPERIMENTAL
Intervention: Noisy galvanic vestibular stimulation (nGVS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33407345

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy at the most pain-sensitive segment
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy at the stiffest segment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 132
Study: 32105621

Group type: EXPERIMENTAL
Intervention: NYDA® (a mixture of two dimeticones with different viscosity)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Dimeticones (general)
Number of subjects: 106
Study: 35179802

Group type: EXPERIMENTAL
Intervention: Intermittent fasting for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (standard care group)
Number of subjects: 0
Study: 33761968

Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional randomized clinical trials
Number of subjects: 0
Study: 35925834

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler with lidocaine (HARL)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 148
Study: 32379165

Group type: EXPERIMENTAL
Intervention: Topical almond oil (6.5 cc applied daily for 7 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (liquid paraffin, 6.5 cc applied daily for 7 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Topical almond oil
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (liquid paraffin)
Number of subjects: 108
Study: 35969578

Group type: EXPERIMENTAL
Intervention: Player-labelling (maturation-ordered shirt numbers)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uninformed scouts
Number of subjects: 24
Study: 32276866

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 579
Study: 34190995

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 565
Study: 34550812

Group type: EXPERIMENTAL
Intervention: AMBU AuraGain
Number of subjects: 120

Group type: COMPARATOR
Intervention: LMA Supreme
Number of subjects: 120
Study: 33596508

Group type: EXPERIMENTAL
Intervention: VLCHF diet
Number of subjects: 24
Study: 32319999

Group type: EXPERIMENTAL
Intervention: NT‐proBNP‐guided treatment (goal to suppress NT‐proBNP concentrations to <1000 pg/mL)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Higher doses of β‐blockers
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Higher doses of ACE inhibitors
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Higher doses of ARBs
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Increasing doses of mineralocorticoid antagonists
Number of subjects: 894
Study: 33228733

Group type: EXPERIMENTAL
Intervention: Early essential newborn care (EENC)
Number of subjects: 1349
Study: 35947884

Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment for three weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no open-label placebo treatment)
Number of subjects: 89
Study: 33788987

Group type: COMPARATOR
Intervention: LED-RL irradiation at fluences of 160, 320, or 480 J/cm2, triweekly for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: LED-RL irradiation at certain fluences
Number of subjects: 0

Group type: COMPARATOR
Intervention: LED-RL phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adverse events from LED-RL treatment
Number of subjects: 0
Study: 32718927

Group type: EXPERIMENTAL
Intervention: Breaking up sitting with 3-min bouts of light-intensity walking every 30 mins
Number of subjects: 208

Group type: COMPARATOR
Intervention: Sitting condition (remaining seated during work shifts)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 5 hour sleep opportunity
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 9 hour sleep opportunity
Number of subjects: 208
Study: 35598501

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 34536355

Group type: EXPERIMENTAL
Intervention: Severe stage 2 hypertension
Number of subjects: 0

Group type: COMPARATOR
Intervention: All higher blood pressure categories
Number of subjects: 0

Group type: COMPARATOR
Intervention: All lower blood pressure categories
Number of subjects: 0
Study: 34151132

Group type: EXPERIMENTAL
Intervention: 3 months of adjuvant afatinib (30 mg by mouth daily)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 2 years of adjuvant afatinib (30 mg by mouth daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of 2 years vs 3 months of adjuvant afatinib
Number of subjects: 46
Study: 32540134

Group type: COMPARATOR
Intervention: Older adults during speech production and limb movement tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: EEG activities in older adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faster motor reaction times in younger adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre‐motor components of alpha and beta activities in older adults
Number of subjects: 0
Study: 35091162

Group type: EXPERIMENTAL
Intervention: Relative ST events with an optimal cut-off at an increment of 85% from baseline
Number of subjects: 1328
Study: 34156697

Group type: EXPERIMENTAL
Intervention: Olfactory rehabilitation plus daily oral supplement with Palmitoylethanolamide (PEA) and Luteolin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Olfactory rehabilitation alone
Number of subjects: 12
Study: 35850742

Group type: EXPERIMENTAL
Intervention: Daily Contact Testing (DCT) using Lateral Flow Test (LFT) and two Polymerase Chain Reaction (PCR) tests for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard self-isolation with one PCR test for 10 days
Number of subjects: 60
Study: 34281401

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) for 12 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 33127945

Group type: EXPERIMENTAL
Intervention: 75/650 mg tramadol with paracetamol every 8 hours
Number of subjects: 117

Group type: COMPARATOR
Intervention: 37.5/325 mg tramadol with paracetamol every 8 hours
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study: 35897488

Group type: EXPERIMENTAL
Intervention: Expert message source
Number of subjects: 302

Group type: COMPARATOR
Intervention: Peer message source
Number of subjects: 302
Study: 34156898

Group type: EXPERIMENTAL
Intervention: Romyelocel-L infusion on d9 with granulocyte colony-stimulating factor (G-CSF) starting daily d14
Number of subjects: 163

Group type: COMPARATOR
Intervention: G-CSF daily alone on d14 (control)
Number of subjects: 163
Study: 32093667

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (3% hydrogen peroxide and tap water)
Number of subjects: 23
Study: 34459905

Group type: EXPERIMENTAL
Intervention: Mobile app for pediatric drug preparation (n = 74)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional drug preparation methods (n = 76)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 150
Study: 34978535

Group type: EXPERIMENTAL
Intervention: Foundations app
Number of subjects: 136
Study: 32844703

Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training; 6 × 20 sec at 140% Wmax)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MICT (moderate-intensity continuous training; 45 min at 70% Wmax)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON (non-exercise trial)
Number of subjects: 10
Study: 33636430

Group type: EXPERIMENTAL
Intervention: Overfed diet (HIGH; n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CON‐ diet meeting nutrient requirement; n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both HIGH and CON groups
Number of subjects: 16
Study: 35192655

Group type: EXPERIMENTAL
Intervention: 90-day vaginal ring containing tenofovir for HIV prevention
Number of subjects: 49
Study: 34233965

Group type: EXPERIMENTAL
Intervention: Nangibotide (two doses)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Nangibotide
Number of subjects: 450
Study: 33512812

Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy (CAES)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Both CAES and EVL
Number of subjects: 240
Study: 33985681

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 19220

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 19220
Study: 32585284

Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange (TPE)
Number of subjects: 31
Study: 33300284

Group type: EXPERIMENTAL
Intervention: State gratitude
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Trait gratitude
Number of subjects: 326
Study: 34157417

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Number of subjects: 894

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 894
Study: 36220481

Group type: EXPERIMENTAL
Intervention: PSE-enhanced conventional care
Number of subjects: 148

Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 148
Study: 32720780

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 16
Study: 32812666

Group type: EXPERIMENTAL
Intervention: Partial circumferential epitendinous suture (180° on the palmar side)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Complete circumferential epitendinous suture (360° and double knotting technique)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Complete circumferential epitendinous suture (360° and single knotting technique)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Complete circumferential epitendinous suture (both single and double knotting techniques)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Complete circumferential epitendinous suture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Partial circumferential epitendinous suture
Number of subjects: 36
Study: 33651448

Group type: EXPERIMENTAL
Intervention: rs671 GA/AA genotype
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Poor control of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, blood pressure, and glycated levels
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Drinking alcohol
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Cox regression analysis
Number of subjects: 2500
Study: 32355123

Group type: EXPERIMENTAL
Intervention: Besifovir dipivoxil maleate (BSV) for 144 weeks
Number of subjects: 197

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) followed by BSV for 96 weeks
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: BSV for 144 weeks
Number of subjects: 197

Group type: COMPARATOR
Intervention: TDF followed by BSV
Number of subjects: 197
Study: 36174092

Group type: EXPERIMENTAL
Intervention: Care priorities for severe pediatric TBI before the COVID-19 pandemic (2019)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Care priorities for severe pediatric TBI during the COVID-19 pandemic (2021)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of care priorities between 2019 and 2021
Number of subjects: 15

Group type: COMPARATOR
Intervention: Association of hospital volume and subspecialty resource availability with prioritization of key process actions
Number of subjects: 15
Study: 32561404

Group type: EXPERIMENTAL
Intervention: Maternal 25-hydroxyvitamin D levels in the first half of pregnancy
Number of subjects: 2134

Group type: COMPARATOR
Intervention: Matched controls (not specified)
Number of subjects: 2134
Study: 32911981

Group type: EXPERIMENTAL
Intervention: HBP with visualization of the tricuspid valve annulus
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard method of HBP implantation
Number of subjects: 50
Study: 34614447

Group type: EXPERIMENTAL
Intervention: SEP‐4199 200 mg/d
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: SEP‐4199 400 mg/d
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 34750553

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 200 mg twice daily
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 150 mg daily
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 50 mg daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fenebrutinib (all doses)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 150 mg daily and 200 mg twice daily
Number of subjects: 93
Study: 34561715

Group type: EXPERIMENTAL
Intervention: Discontinuation of estradiol (E2) after observation of a gestational sac and heartbeat (study group)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Continued estradiol (E2) administration until week 12 of gestational age (control group)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Both groups continued progesterone-in-oil administration until week 12 of gestational age
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Measurement of serum levels for E2 and progesterone
Number of subjects: 291

Group type: COMPARATOR
Intervention: Maternal complications
Number of subjects: 291
Study: 33604969

Group type: EXPERIMENTAL
Intervention: Preemptive clobetasol 0.05% cream applied twice per day for 8 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Reactive clobetasol 0.05% cream applied twice per day for 8 weeks
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Preemptive clobetasol
Number of subjects: 116

Group type: COMPARATOR
Intervention: Reactive clobetasol
Number of subjects: 116
Study: 32182674

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) during exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (aerobic and strength training without WB-EMS)
Number of subjects: 34
Study: 34289481

Group type: EXPERIMENTAL
Intervention: Prosody Treatment Program (1 hour, once per week for 3 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional auditory and language training (control)
Number of subjects: 34
Study: 33159697

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) video intervention
Number of subjects: 2538

Group type: COMPARATOR
Intervention: Usual ACP practices (Control)
Number of subjects: 2538
Study: 35240053

Group type: EXPERIMENTAL
Intervention: Elective ipsilateral upper-neck irradiation (UNI)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Whole-neck irradiation (WNI)
Number of subjects: 446
Study: 32461626

Group type: EXPERIMENTAL
Intervention: Expression initiation within 181–360 minutes following delivery
Number of subjects: 180

Group type: COMPARATOR
Intervention: Expression initiation within 60 minutes following delivery
Number of subjects: 180

Group type: COMPARATOR
Intervention: Expression initiation within 61–180 minutes following delivery
Number of subjects: 180
Study: 36201966

Group type: EXPERIMENTAL
Intervention: Facilitated tucking position (n=44)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Routine application (n=45)
Number of subjects: 89
Study: 33373806

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 32334478

Group type: EXPERIMENTAL
Intervention: 7-day regimen of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 14-day regimen of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 14-day regimen
Number of subjects: 77
Study: 35685075

Group type: EXPERIMENTAL
Intervention: Peer-mediated intervention (PMI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Behavioral therapy based on applied behavior analysis (ABA) (control group)
Number of subjects: 55
Study: 33172491

Group type: EXPERIMENTAL
Intervention: Interest in Japan's policy on recruiting EPA nurses
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Intention to recruit EPA nurses
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Interest in the policy (predictor for recruitment intention)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Perception of EPA nurses (predictor for recruitment intention)
Number of subjects: 432
Study: 35064813

Group type: EXPERIMENTAL
Intervention: Collagen sponge containing simvastatin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (sockets retained the clot)
Number of subjects: 22
Study: 34158293

Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBaP)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Right ventricular apex pacing (RVAP)
Number of subjects: 210
Study: 35960611

Group type: EXPERIMENTAL
Intervention: Systematic Suture (SS)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conservative Management (CM)
Number of subjects: 143